Stocks · Health care · Pharmaceutical Preparations

Zymeworks Inc.

ZYME Clue Score44
United States Fiscal year ends December CIK 0001937653 Results filed 6 Aug 2026

What the insiders did Scheduled selling only

By person

8 insiders · 1 transaction
8.9×

Kenneth Galbraith holds 8.9 times base salary in stock. $5.86M of shares against $656.76K in salary for 2025.

Salary from the company's own proxy. The shares are what Kenneth Galbraith last reported holding, valued at $25.85, the price Common Stock was last bought or sold at on the open market here, on 9 Oct 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Adam Schayowitz
EVP, Head of R&D
—
$357.56K (1) scheduled
−$357.56K
23,205
0.0327%
$599.85K
—
EcoR1 Capital, LLC entity
Director
—
—
—
22,970,388
32.37%
$593.78M
+56.3%
Gregory Austin Ciongoli
Director
—
—
—
488,500
0.6884%
$12.63M
+564.6%
Kenneth Galbraith
Chair & CEO
—
—
—
226,842
0.3197%
$5.86M
+854.6%
Mark Hollywood
EVP & Chief Operating Officer
—
—
—
133,852
0.1886%
$3.46M
+10.3%
Paul Andrew Moore
Chief Scientific Officer
—
—
—
48,497
0.0683%
$1.25M
+558.3%
Jeffrey T L Smith
EVP & Chief Medical Officer
—
—
—
26,708
0.0376%
$690.40K
—
Leone D Patterson
EVP, Chief Bus & Fin Officer
—
—
—
459
0.0006%
$11.87K
—